Kezar Life Sciences Inc. (KZR) has recently experienced a decrease in its stock performance. However, analysts remain optimistic about its potential for growth in the future, with a forecasted price point of $16.67. The company’s capital structure shows a debt to equity ratio of 7.88 and a liquidity ratio of 25.98. Reports suggest there have been several insider trading activities at KZR.
Despite the stock’s recent performance, Wells Fargo rated KZR stocks as “Overweight,” and some analysts have given it a “buy” or “hold” rating. KZR is currently trading at a significant distance from its 50-day moving average and 52-week high.
Kezar Life Sciences Inc. (NASDAQ: KZR) has seen an increase of 5.97% in its stock price, currently priced at $2.32. Despite this, the company has experienced a -3.27% fall in its stock price over the past week, with a -42.74% drop in the past month and a -49.93% fall in the past quarter. The average price point forecasted by analysts for KZR is $16.67, which is $13.95 above the current market price.
The public float for KZR is 54.06 million, and short sellers currently hold a 9.04% ratio of that float. As of March 28, 2023, the average trading volume of KZR was 731.57K shares. Wells Fargo has predicted a price target of $19 and rated KZR stocks as “Overweight” in their research note published on December 08, 2021.
KZR’s market performance indicates a volatility ratio of 7.71% for the week and 8.58% for the past 30 days. The simple moving average for the last 20 days is -26.30%, with a simple moving average of -53.42% for the last 200 days. KZR is trading at -40.05% from the 50-day moving average and is currently trading -48.55% lower over the past 50 days.
Reports suggest that there have been several insider trading activities at KZR, with Morningside Venture Investment, the 10% owner of Kezar Life Sciences Inc., selling 40,000 shares at $6.88 on February 06 and another 25,000 shares at $7.15 on February 03. Morningside Venture Investment now owns 5,447,993 shares of Kezar Life Sciences Inc., valued at $275,320 using the latest closing price.
Overall, the stock fundamentals for KZR indicate a significant decrease in its market performance over the past month and quarter. However, analysts remain optimistic about its potential for growth in the future.
Kezar Life Sciences Inc. (KZR) has a total capital return value set at -28.38, with invested capital returns at -27.39. The equity return is -25.20, while asset returns stand at -23.30. KZR’s capital structure shows a debt to equity ratio of 7.88, a total debt to capital ratio of 7.30, and a total debt to assets ratio of 7.10. The liquidity ratio for KZR is 25.98.
Although the company has had a bad performance in recent times, analysts remain bullish about the stock, with some rating it as a “buy” and others as a “hold”. It’s worth noting that KZR is currently trading at a significant distance from its 50-day moving average and 52-week high.
Don’t miss interesting posts on Famousbio
